Disentangling Afroasiatic *t-morphemes
Brill's Journal of Afroasiatic Languages and Linguistics · 22.06.2026 · 18 (1) · 287-314
DOI: 10.1163/18776930-01801006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brill's Journal of Afroasiatic Languages and Linguistics, erschienen am 22.06.2026. Verfasst von Lameen Souag. Die Arbeit nennt 166 Literaturangaben.
Abstract (Originalsprache)
“Middle” t , with functions ranging from autobenefactive to passive and beyond, is one of the best known cross-Afroasiatic cognates within derivational morphology, along with causative s . In some cases, its functions appear to extend beyond diathesis into the domain of aspect; whereas causative s has remained aloof from TAM , middle t has been argued to have developed imperfective functions in at least three branches of Afroasiatic: West Rift Cushitic, Akkadian (Semitic), and Berber. Yet voice morphology is not a typical source for aspectual morphology cross-linguistically, and grammaticalisation pathways deriving imperfective from middle, specifically, appear poorly attested and difficult to motivate conceptually. This paper seeks to eliminate this apparent paradox, arguing that West Rift and Akkadian developments reflect fusion with earlier imperfective markers, and putting forward a novel hypothesis in which imperfective t in Berber is derived from another morpheme with reflexes in both Berber and Semitic: nominalizing t .
Zitieren
APA
Souag, L. (2026). Disentangling Afroasiatic *t-morphemes. Brill's Journal of Afroasiatic Languages and Linguistics, 18(1), 287-314. https://doi.org/10.1163/18776930-01801006
Vancouver
Souag L. Disentangling Afroasiatic *t-morphemes. Brill's Journal of Afroasiatic Languages and Linguistics. 2026;18(1):287-314. doi:10.1163/18776930-01801006
BibTeX
@article{Souag2026,
author = {Souag, Lameen},
title = {Disentangling Afroasiatic *t-morphemes},
journal = {Brill's Journal of Afroasiatic Languages and Linguistics},
year = {2026},
volume = {18},
number = {1},
pages = {287--314},
doi = {10.1163/18776930-01801006}
}
EUVIMED